Literature DB >> 33716487

Glucosuria Is Not Always Due to Diabetes.

Meghan Lewis1, Bhagwan Dass1.   

Abstract

Further study of the long-term implications and follow-up is needed on SGLT2 mutation, an uncommon cause of glucosuria that mimics the effect of SGLT2 inhibitors, including the possible development of further renal disease, type 2 diabetes mellitus, and cardiovascular disease.
Copyright © 2021 Frontline Medical Communications Inc., Parsippany, NJ, USA.

Entities:  

Year:  2021        PMID： 33716487      PMCID： PMC7953860          DOI： 10.12788/fp.0091

Source DB:  PubMed          Journal:  Fed Pract        ISSN： 1078-4497


  9 in total

Review 1.  An update on sodium-glucose co-transporter-2 inhibitors for the treatment of diabetes mellitus.

Authors:  Daniel S Hsia; Owen Grove; William T Cefalu
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2017-02       Impact factor: 3.243

Review 2.  Safety of Sodium-Glucose Co-Transporter 2 Inhibitors.

Authors:  Janet B McGill; Savitha Subramanian
Journal:  Am J Cardiol       Date:  2019-12-15       Impact factor: 2.778

3.  SGLT2 inhibitors for primary prevention of cardiovascular events.

Authors:  Itamar Raz; Simona Cernea; Avivit Cahn
Journal:  J Diabetes       Date:  2019-11-21       Impact factor: 4.006

4.  Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.

Authors:  Bernard Zinman; Christoph Wanner; John M Lachin; David Fitchett; Erich Bluhmki; Stefan Hantel; Michaela Mattheus; Theresa Devins; Odd Erik Johansen; Hans J Woerle; Uli C Broedl; Silvio E Inzucchi
Journal:  N Engl J Med       Date:  2015-09-17       Impact factor: 91.245

Review 5.  International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma.

Authors:  S Vincent Rajkumar; Meletios A Dimopoulos; Antonio Palumbo; Joan Blade; Giampaolo Merlini; María-Victoria Mateos; Shaji Kumar; Jens Hillengass; Efstathios Kastritis; Paul Richardson; Ola Landgren; Bruno Paiva; Angela Dispenzieri; Brendan Weiss; Xavier LeLeu; Sonja Zweegman; Sagar Lonial; Laura Rosinol; Elena Zamagni; Sundar Jagannath; Orhan Sezer; Sigurdur Y Kristinsson; Jo Caers; Saad Z Usmani; Juan José Lahuerta; Hans Erik Johnsen; Meral Beksac; Michele Cavo; Hartmut Goldschmidt; Evangelos Terpos; Robert A Kyle; Kenneth C Anderson; Brian G M Durie; Jesus F San Miguel
Journal:  Lancet Oncol       Date:  2014-10-26       Impact factor: 41.316

6.  Renal glucosuria due to SGLT2 mutations.

Authors:  Robert Kleta; Caroline Stuart; Fred A Gill; William A Gahl
Journal:  Mol Genet Metab       Date:  2004-05       Impact factor: 4.797

7.  Twenty-one additional cases of familial renal glucosuria: absence of genetic heterogeneity, high prevalence of private mutations and further evidence of volume depletion.

Authors:  Joaquim Calado; Yves Sznajer; Daniel Metzger; Ana Rita; Marie C Hogan; Antonis Kattamis; Mauro Scharf; Velibor Tasic; Johann Greil; Florian Brinkert; Markus J Kemper; René Santer
Journal:  Nephrol Dial Transplant       Date:  2008-07-12       Impact factor: 5.992

8.  A Case of Isolated Glycosuria Mediated by an SLC5A2 Gene Mutation and Characterized by Postprandial Heavy Glycosuria Without Salt Wasting.

Authors:  Kyeong Min Kim; Soon Kil Kwon; Hye-Young Kim
Journal:  Electrolyte Blood Press       Date:  2016-12-31

Review 9.  Empagliflozin: a new sodium-glucose co-transporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes.

Authors:  Joshua J Neumiller
Journal:  Drugs Context       Date:  2014-06-11
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.